Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Small Cell Lung Carcinoma 3Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Osteosarcoma 1Nasopharyngeal Carcinoma 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 139pembrolizumab 88Carboplatin 73Radiotherapy 71Cetuximab 69Docetaxel 58Paclitaxel 52Radiotherapy, Intensity-Modulated 43Fluorouracil 43Nivolumab 32Surgical Procedures, Operative 18Albumin-Bound Paclitaxel 15130-nm albumin-bound paclitaxel 15Radiation 14Drug Therapy 14tislelizumab 13Taxes 13durvalumab 12Magnetic Resonance Spectroscopy 12toripalimab 11camrelizumab 11Platinum 11Chemoradiotherapy 11Biopsy 11cemiplimab 10Radiosurgery 10Erlotinib Hydrochloride 10Capecitabine 10Specimen Handling 9Neoadjuvant Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Squamous Cell Carcinoma of Head and Neck × lobaplatin × Clear all
NCT06170697 2023-12-20

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡